Clinical Trials Sponsored by Virogin Biotech Canada Ltd

Total 13 results

Virogin Biotech Canada Ltd

Recruiting

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma

United States
Virogin Biotech Canada Ltd

Recruiting

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Solid Tumor

United States
Shanghai Virogin Biotech Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors

Advanced Malignant Solid Tumor

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Not yet recruiting

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Primary Hepatocellular Carcinoma
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumor

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Unknown

Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer

Primary Liver Cancer

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Metastatic Gastric Cancer

China
CNBG-Virogin Biotech (Shanghai) Ltd.
Shulan (Hangzhou) Hospital

Recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Unknown

Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

Lymphoma | Leukemia
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia

Leukemia
The First Affiliated Hospital of Soochow University
Biotech Pharmaceutical Co., Ltd.; Cinda Biopharmaceutical (Suzhou) Co., Ltd.

Not yet recruiting

Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. (Carpp-1)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

3

Subscribe